559 related articles for article (PubMed ID: 29242014)
1. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial.
Andorf S; Purington N; Block WM; Long AJ; Tupa D; Brittain E; Rudman Spergel A; Desai M; Galli SJ; Nadeau KC; Chinthrajah RS
Lancet Gastroenterol Hepatol; 2018 Feb; 3(2):85-94. PubMed ID: 29242014
[TBL] [Abstract][Full Text] [Related]
2. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy.
Wood RA; Kim JS; Lindblad R; Nadeau K; Henning AK; Dawson P; Plaut M; Sampson HA
J Allergy Clin Immunol; 2016 Apr; 137(4):1103-1110.e11. PubMed ID: 26581915
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab for the Treatment of Multiple Food Allergies.
Wood RA; Togias A; Sicherer SH; Shreffler WG; Kim EH; Jones SM; Leung DYM; Vickery BP; Bird JA; Spergel JM; Iqbal A; Olsson J; Ligueros-Saylan M; Uddin A; Calatroni A; Huckabee CM; Rogers NH; Yovetich N; Dantzer J; Mudd K; Wang J; Groetch M; Pyle D; Keet CA; Kulis M; Sindher SB; Long A; Scurlock AM; Lanser BJ; Lee T; Parrish C; Brown-Whitehorn T; Spergel AKR; Veri M; Hamrah SD; Brittain E; Poyser J; Wheatley LM; Chinthrajah RS
N Engl J Med; 2024 Mar; 390(10):889-899. PubMed ID: 38407394
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued
Andorf S; Purington N; Kumar D; Long A; O'Laughlin KL; Sicherer S; Sampson H; Cianferoni A; Whitehorn TB; Petroni D; Makhija M; Robison RG; Lierl M; Logsdon S; Desai M; Galli SJ; Rael E; Assa'ad A; Chinthrajah S; Pongracic J; Spergel JM; Tam J; Tilles S; Wang J; Nadeau K
EClinicalMedicine; 2019 Jan; 7():27-38. PubMed ID: 31193674
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
Jones SM; Kim EH; Nadeau KC; Nowak-Wegrzyn A; Wood RA; Sampson HA; Scurlock AM; Chinthrajah S; Wang J; Pesek RD; Sindher SB; Kulis M; Johnson J; Spain K; Babineau DC; Chin H; Laurienzo-Panza J; Yan R; Larson D; Qin T; Whitehouse D; Sever ML; Sanda S; Plaut M; Wheatley LM; Burks AW;
Lancet; 2022 Jan; 399(10322):359-371. PubMed ID: 35065784
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients.
Schneider LC; Rachid R; LeBovidge J; Blood E; Mittal M; Umetsu DT
J Allergy Clin Immunol; 2013 Dec; 132(6):1368-74. PubMed ID: 24176117
[TBL] [Abstract][Full Text] [Related]
9. Oral immunotherapy and potential treatment.
Sato S; Yanagida N; Ebisawa M
Chem Immunol Allergy; 2015; 101():106-13. PubMed ID: 26022870
[TBL] [Abstract][Full Text] [Related]
10. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
Jat KR; Walia DK; Khairwa A
Cochrane Database Syst Rev; 2015 Nov; (11):CD010288. PubMed ID: 26545165
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy.
Frischmeyer-Guerrerio PA; Masilamani M; Gu W; Brittain E; Wood R; Kim J; Nadeau K; Jarvinen KM; Grishin A; Lindblad R; Sampson HA
J Allergy Clin Immunol; 2017 Oct; 140(4):1043-1053.e8. PubMed ID: 28414061
[TBL] [Abstract][Full Text] [Related]
12. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
[TBL] [Abstract][Full Text] [Related]
13. Two-step egg introduction for prevention of egg allergy in high-risk infants with eczema (PETIT): a randomised, double-blind, placebo-controlled trial.
Natsume O; Kabashima S; Nakazato J; Yamamoto-Hanada K; Narita M; Kondo M; Saito M; Kishino A; Takimoto T; Inoue E; Tang J; Kido H; Wong GW; Matsumoto K; Saito H; Ohya Y;
Lancet; 2017 Jan; 389(10066):276-286. PubMed ID: 27939035
[TBL] [Abstract][Full Text] [Related]
14. Clinical aspects of oral immunotherapy for the treatment of allergies.
Yanagida N; Sato S; Ebisawa M
Semin Immunol; 2017 Apr; 30():45-51. PubMed ID: 28780220
[TBL] [Abstract][Full Text] [Related]
15. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab facilitates rapid oral desensitization for peanut allergy.
MacGinnitie AJ; Rachid R; Gragg H; Little SV; Lakin P; Cianferoni A; Heimall J; Makhija M; Robison R; Chinthrajah RS; Lee J; Lebovidge J; Dominguez T; Rooney C; Lewis MO; Koss J; Burke-Roberts E; Chin K; Logvinenko T; Pongracic JA; Umetsu DT; Spergel J; Nadeau KC; Schneider LC
J Allergy Clin Immunol; 2017 Mar; 139(3):873-881.e8. PubMed ID: 27609658
[TBL] [Abstract][Full Text] [Related]
17. AR101 Oral Immunotherapy for Peanut Allergy.
; Vickery BP; Vereda A; Casale TB; Beyer K; du Toit G; Hourihane JO; Jones SM; Shreffler WG; Marcantonio A; Zawadzki R; Sher L; Carr WW; Fineman S; Greos L; Rachid R; Ibáñez MD; Tilles S; Assa’ad AH; Nilsson C; Rupp N; Welch MJ; Sussman G; Chinthrajah S; Blumchen K; Sher E; Spergel JM; Leickly FE; Zielen S; Wang J; Sanders GM; Wood RA; Cheema A; Bindslev-Jensen C; Leonard S; Kachru R; Johnston DT; Hampel FC; Kim EH; Anagnostou A; Pongracic JA; Ben-Shoshan M; Sharma HP; Stillerman A; Windom HH; Yang WH; Muraro A; Zubeldia JM; Sharma V; Dorsey MJ; Chong HJ; Ohayon J; Bird JA; Carr TF; Siri D; Fernández-Rivas M; Jeong DK; Fleischer DM; Lieberman JA; Dubois AEJ; Tsoumani M; Ciaccio CE; Portnoy JM; Mansfield LE; Fritz SB; Lanser BJ; Matz J; Oude Elberink HNG; Varshney P; Dilly SG; Adelman DC; Burks AW
N Engl J Med; 2018 Nov; 379(21):1991-2001. PubMed ID: 30449234
[TBL] [Abstract][Full Text] [Related]
18. Oral Immunotherapy for Food Allergy.
Wood RA
J Investig Allergol Clin Immunol; 2017; 27(3):151-159. PubMed ID: 28102823
[TBL] [Abstract][Full Text] [Related]
19. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
Jat KR; Walia DK; Khairwa A
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD010288. PubMed ID: 29551015
[TBL] [Abstract][Full Text] [Related]
20. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
Casale TB; Condemi J; LaForce C; Nayak A; Rowe M; Watrous M; McAlary M; Fowler-Taylor A; Racine A; Gupta N; Fick R; Della Cioppa G;
JAMA; 2001 Dec; 286(23):2956-67. PubMed ID: 11743836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
